Harbour BioMed Wins $20.2 Million Patent Verdict Against Amgen in Delaware Court
Harbour BioMed (HKG: 2142) announced that a jury in the U.S. District Court for the...
Sichuan Biokin’s Iza-Bren Becomes World’s First EGFR×HER3 Bispecific ADC with NDA Accepted by China’s NMPA
Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that the new drug application (NDA) for...
SSY Group Secures Exclusive China License for OPT101, Novel Peritoneal Dialysis Therapy from Opterion Health
SSY Group Limited (HKG: 2005) announced it has entered into a letter of intent with...
Simcere Pharmaceutical Partners with Stanford University to Develop First-in-Class IPF Therapy
Simcere Pharmaceutical Group (HKG: 2096) announced a collaborative research agreement with Stanford University School of...
Novo Nordisk to Fully Launch Sogroya in China This Summer for Pediatric Growth Hormone Deficiency
Novo Nordisk (NYSE: NVO) announced that its long-acting growth hormone injection Sogroya (somapacitan) will be...
Medtronic Completes $550 Million Acquisition of Scientia Vascular to Strengthen Neurovascular Portfolio
Medtronic (NYSE: MDT) announced on June 12, 2026 the completion of its acquisition of Scientia...
Sanofi’s Tzield Receives FDA Approval to Preserve Insulin Production in Recently Diagnosed Type 1 Diabetes
Sanofi (NASDAQ: SNY) announced that the U.S. Food and Drug Administration (FDA) has granted accelerated...
Roche’s VENTANA PTEN Assay Receives FDA Approval as First Companion Diagnostic for AstraZeneca’s Truqap in Prostate Cancer
Roche Holding AG (SWX: ROP, OTCMKTS: RHHBY) announced that the VENTANA PTEN (SP218) RxDx Assay...
Jazz Pharmaceuticals Reports Phase 3 LAGOON Trial Misses Primary Endpoint for Zepzelca in Relapsed Small Cell Lung Cancer
Jazz Pharmaceuticals (NASDAQ: JAZZ) announced on June 12, 2026 that the Phase 3 LAGOON trial,...
AstraZeneca’s Truqap Receives FDA Approval as First Targeted Therapy for PTEN-Deficient Prostate Cancer
AstraZeneca plc (NYSE: AZN) announced that the U.S. Food and Drug Administration (FDA) has approved...
Micot Pharmaceutical Successfully Lists on Hong Kong Stock Exchange with HK$1.22 Billion IPO
Shaanxi Micot Pharmaceutical Technology Co., Ltd. (HKG: 2355) announced its successful listing on the Hong...
Merck Secures FDA Approval for Keytruda-Welireg Combination as Adjuvant Therapy in High-Risk Kidney Cancer
Merck & Co., Inc. (MSD; NYSE: MRK) announced that the U.S. Food and Drug Administration...
China’s NHSA Receives Record 818 Drug Applications for 2026 National Reimbursement Drug List Adjustment
China’s National Healthcare Security Administration (NHSA) announced that the application period for the 2026 adjustment...
Simcere Pharmaceutical Secures NMPA Approval for SIM0689 Bispecific Antibody Targeting PD-1 and VEGF in Solid Tumors
Simcere Pharmaceutical Group (HKG: 2096) announced that SIM0689, a novel bispecific antibody (BsAb) targeting both...
Mabwell Bioscience Secures FDA Approval for 6MW5311 Bispecific Antibody Trial in Hematologic Malignancies
Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) announced that the U.S. Food and Drug Administration...
Qingfeng Pharmaceutical Group Partners with TASCO PHARMA to Commercialize Anti-Tumor and CNS Medicines in Vietnam
Qingfeng Pharmaceutical Group announced a strategic commercialization cooperation agreement with Vietnam’s TASCO PHARMA for the...
Merck Secures NMPA Approval for Enflonsia (Clesrovimab) – First Single-Dose RSV Monoclonal Antibody in China
Merck & Co., Inc. (MSD, NYSE: MRK) announced that China’s National Medical Products Administration (NMPA)...
Junshi Biosciences Secures Global Exclusive Rights to CAS’s Tetravalent Recombinant Dengue Vaccine in Landmark Licensing Deal
Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180), a China-based biopharmaceutical company, has struck...
Shouyao Holdings Secures NMPA Approval for Second-Generation ALK Inhibitor CT-707 as First-Line Treatment for ALK-Positive NSCLC
Shouyao Holdings (Beijing) Co., Ltd. (SHA: 688197), a Beijing-based pharmaceutical company, announced it has received...
Createrna’s MY008211A Becomes China’s First Home-Grown Oral CFB Inhibitor Approved for Paroxysmal Nocturnal Hemoglobinuria
Wuhan Createrna Science and Technology Co., Ltd., a China-based biopharmaceutical company, announced it has received...